Metagenomi, Inc. Common Stock
Metagenomi Therapeutics, Inc. a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration an… Read more
Metagenomi, Inc. Common Stock (MGX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.119x
Based on the latest financial reports, Metagenomi, Inc. Common Stock (MGX) has a cash flow conversion efficiency ratio of -0.119x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.25 Million) by net assets ($178.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Metagenomi, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Metagenomi, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Metagenomi, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Metagenomi, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cementos Bio-B
SN:CEMENTOS
|
-0.003x |
|
Shougang Concord Century Holdings Limited
F:CW7
|
0.013x |
|
Ddev Plastiks Industries Limited
NSE:DDEVPLSTIK
|
N/A |
|
Digital Brands Group Inc
NASDAQ:DBGIW
|
-28.437x |
|
Jinxin Technology Holding Company American Depositary Shares
NASDAQ:NAMI
|
0.019x |
|
OS Therapies Incorporated
NYSE MKT:OSTX
|
-1.000x |
|
STEP Energy Services Ltd
PINK:SNVVF
|
0.058x |
|
BRISANET ON NM
SA:BRST3
|
0.061x |
Annual Cash Flow Conversion Efficiency for Metagenomi, Inc. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of Metagenomi, Inc. Common Stock from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $234.86 Million | $-109.07 Million | -0.464x | -9.32% |
| 2023-09-30 | $215.17 Million | $-91.41 Million | -0.425x | -6.37% |
| 2022-09-30 | $-74.43 Million | $29.72 Million | -0.399x | +46.42% |
| 2021-09-30 | $-32.54 Million | $24.26 Million | -0.745x | -- |